Key result
Pelacarsen lowered Lipoprotein(a) but did not significantly reduce the primary cardiovascular endpoint in the Lp(a)HORIZON population according to sponsor-reported topline data.
Why the study?
Lipoprotein(a) contributes to residual cardiovascular risk after myocardial infarction, but the clinical benefit of selective pharmacological Lp(a) lowering remains unresolved.
Answers are grounded in this paper and cite their sources.
This narrative review underscores the importance of Lp(a) in post-MI residual risk, while noting that outcome trials are still needed to determine if selectively lowering Lp(a) improves cardiovascular outcomes.
Lipoprotein(a) [Lp(a)] is a highly heritable apoB-containing lipoprotein and a causal contributor to atherosclerotic cardiovascular disease that may contribute to residual cardiovascular risk after myocardial infarction (MI), while the clinical benefit of selective pharmacological Lp(a) lowering remains unresolved. This narrative review examines Lp(a) as a determinant of residual and recurrent cardiovascular risk after MI, integrating molecular biology, human genetics, coronary imaging, post-MI observational studies, measurement considerations, current management, and emerging therapies. Elevated Lp(a) has been associated with coronary plaque progression, high-risk plaque features, oxidized-phospholipid-related inflammatory pathways, recurrent ischemic events, and repeat revascularization, although prognostic associations vary across populations and endpoints. Because concentrations measured during acute MI may underestimate the stable Lp(a) phenotype in some patients, selective repeat measurement after clinical stabilization may be appropriate when classification could influence management or trial eligibility. Contemporary treatment remains centered on intensive control of LDL-C and other modifiable risk factors, while antisense oligonucleotides, small interfering RNAs, and oral particle-assembly inhibitors can produce profound Lp(a) reductions. According to sponsor-reported topline data released in September 2026, pelacarsen lowered Lp(a) but did not significantly reduce the prespecified primary cardiovascular endpoint in the overall Lp(a)HORIZON population; complete peer-reviewed results are not yet available. The sponsor-reported neutral HORIZON topline result raises unresolved questions regarding baseline Lp(a) and absolute reduction, timing of intervention and disease stage, and endpoint composition. Full peer-reviewed HORIZON data and ongoing cardiovascular outcome trials will be required to determine whether and under what conditions selective Lp(a) lowering translates into cardiovascular benefit.
No takes yet. Share an insight, caveat, or question.
Gogan et al. (2026) conducted a review in Myocardial infarction and elevated Lipoprotein(a). Selective Lipoprotein(a) lowering therapies (e.g., pelacarsen) was evaluated. Pelacarsen lowered Lipoprotein(a) but did not significantly reduce the primary cardiovascular endpoint in the Lp(a)HORIZON population according to sponsor-reported topline data.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: